a2 Milk shares fall sharply after Middle East freight disruption cuts into China infant formula supply
Shares in a2 Milk fell more than 16 per cent on the New Zealand Exchange today, sliding to $8.99 as investors absorbed the full weight of a supply chain crisis the company has warned will materially reduce its China infant formula sales through at least May this year.
The baby formula group, which built its premium reputation around the naturally occurring A2 beta-casein protein found in its milk, revised its full-year profit guidance on 13 April after a series of disruptions compounded to create shortages of its flagship China-label infant milk formula products. While management described the constraints as temporary and largely timing-related, the scale of the revisions rattled investors and the stock has shed roughly 20 per cent from the $11.21 it traded at on 14 April.
At the heart of the problem is the ongoing Middle East conflict. Fighting in the region has severely disrupted air freight routes between key production hubs and China, reducing the availability of cargo capacity and pushing up logistics costs significantly. That disruption alone would have been manageable for a company with a2 Milk’s resources, but it arrived at exactly the same time as a series of other setbacks that made the combined effect severe.
The company’s New Zealand manufacturing partner Synlait Milk had already been working through earlier production difficulties of its own, which left inventory levels running lean when the freight problems hit. On top of that, enhanced quality testing requirements — including new cereulide testing measures on infant formula — extended the time needed to release batches from Synlait’s factories. Any batch requiring retesting added weeks to lead times at exactly the wrong moment. Synlait confirmed this week that production had returned to targeted levels, but the pipeline of finished product had already run dangerously thin.
Chinese customs procedures added further pressure. Increased inspection and sampling rates by border authorities meant goods arriving in the country faced longer clearance times, further slowing the movement of product from the port to supermarket shelves. For a company that relies on consistent availability to maintain its pricing premium over competitors, any gap on shelf translates directly into lost sales and frustrated consumers who may try another brand in the meantime.
The combined effect produced a significant downward revision to a2 Milk’s full-year forecasts. Revenue growth, previously expected at a mid-double-digit pace, is now forecast at a low-to-mid double-digit pace compared with the prior year. EBITDA margin guidance was cut from a range of 15.5 to 16 per cent down to 14.0 to 14.5 per cent as one-off supply chain costs are absorbed into the result. Net profit after tax, which had been expected to rise compared with the year before, is now expected to come in flat or slightly below the prior year’s figure. Cash conversion has been revised to around 50 per cent for the full year, against the 80 per cent previously guided.
In its NZX market update, the company said the disruptions were expected to “materially impact China label IMF in-market product availability during 4Q26, mainly in April and May.” The company noted that delayed cash receipts were also likely to shift into the 2027 financial year because of the later timing of formula sales in the final quarter of this year.
There is an irony buried in the disruption. The company said demand for its China-label a2 products had actually remained robust, partly because a competitor product recall earlier in the year had sent new consumers to the a2 brand, accelerating customer recruitment. The shortfall is not a demand problem — it is purely a supply problem, and one that management expects to be largely resolved as freight routes stabilise and the pipeline of tested and cleared inventory rebuilds.
The broader picture for a2 Milk had been improving before this latest disruption. Its English-label formula lines, including the a2 Platinum and a2 Genesis ranges, were performing well in international markets and were not exposed to the same Chinese customs bottlenecks that have caused much of the clearance delay for China-label products. The company’s presence across multiple markets provides some insulation even as the China supply picture remains difficult.
For shareholders, the central question is how long the constraints persist. If management’s assessment holds and the disruptions are primarily concentrated in April and May, the hit to full-year earnings should be contained and some of the delayed revenue will flow into the next financial year. If Middle East freight markets remain under pressure into the second half of the calendar year, the recovery could take considerably longer than the current guidance suggests.
The sharemarket reaction today reflects genuine uncertainty about that timeline. At $8.99, the stock has given up most of the gains accumulated over the past year, and it remains to be seen whether today’s level represents a floor or whether investors will reassess further as the April and May sales data begins to emerge. RNZ has also been tracking the story as one of the more significant corporate updates to emerge from the NZX this month.
a2 Milk is due to report its full-year results later in the calendar year, which will give investors their clearest view yet of whether the supply chain recovery has taken hold and whether the delayed sales from April and May have successfully converted into revenue in subsequent months. Until that data arrives, the company’s ability to manage the ongoing Middle East freight situation and rebuild product availability across Chinese retail channels will be closely watched by the market.
What do you make of it — are supply chain shocks like this an inevitable risk for export-dependent New Zealand companies, or should a2 Milk have done more to buffer its China business against disruption? Share your thoughts in the comments below.